Palantir Technologies Inc. R&D increased by 12.1% to $160.98M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 19.3%, from $134.89M to $160.98M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 9.5% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $110.52M | $94.32M | $84.18M | $88.60M | $88.17M | $100.86M | $82.04M | $90.10M | $99.53M | $105.71M | $109.28M | $110.04M | $108.78M | $117.56M | $171.50M | $134.89M | $135.04M | $144.19M | $143.55M | $160.98M |
| QoQ Change | — | -14.7% | -10.8% | +5.3% | -0.5% | +14.4% | -18.7% | +9.8% | +10.5% | +6.2% | +3.4% | +0.7% | -1.1% | +8.1% | +45.9% | -21.3% | +0.1% | +6.8% | -0.4% | +12.1% |
| YoY Change | — | — | — | — | -20.2% | +6.9% | -2.5% | +1.7% | +12.9% | +4.8% | +33.2% | +22.1% | +9.3% | +11.2% | +56.9% | +22.6% | +24.1% | +22.7% | -16.3% | +19.3% |